Praxis Precision Medicines (NASDAQ:PRAX) announced Friday that the company will advance its Essential3 program for its lead asset ulixacaltamide against the neurological disorder essential tremor, despite concerns over its ability to succeed.

However, Wedbush downgraded the stock in reaction citing a